SWOG clinical trial number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Open
Phase
Abbreviated Title
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Activated
05/01/2021
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Cisplatin 5-Fluorouracil Carboplatin Doxorubicin Gemcitabine hydrochloride Methotrexate Mitomycin-C Vinblastine Sulfate durvalumab

Other Clinical Trials

S2312
SWOG Clinical Trial Number

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature

Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
4% Accrual
Accrual
4%
Open
Phase
S2210
SWOG Clinical Trial Number

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
9% Accrual
Accrual
9%
Open
Phase
S2200
SWOG Clinical Trial Number

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
16% Accrual
Accrual
16%
Open
Phase